Abstract
Objective: Primary SS is characterized by an increased risk of lymphoma in patients with prelymphomatous manifestations (i.e. myoepithelial sialadenitis or mixed cryoglobulinaemia). Serum B-lymphocyte stimulator (s-BLyS) levels in SS-related B-cell lymphoproliferative disorders were studied by integrating the results with the disease activity score and with molecular analyses of B-cell expansion in the salivary glands. Methods: Seventy-six primary SS patients (with or without lymphoma or prelymphomatous manifestations), 56 HCV-related cryoglobulinaemic vasculitis patients and 55 controls were studied. s-BLyS and molecular analyses of B-cell expansion in the salivary gland tissues were performed. Patients with SS and persistent parotid swelling underwent parotid biopsy. Results: S-BLyS differed between SS subgroups, higher levels being documented in patients with lymphoma or prelymphomatous manifestations vs SS without [1.85 (0.45-4.12) ng/ml vs 1.12 (0.56-1.98) ng/ml; P
Original language | English |
---|---|
Article number | kes180 |
Pages (from-to) | 276-281 |
Number of pages | 6 |
Journal | Rheumatology |
Volume | 52 |
Issue number | 2 |
DOIs | |
Publication status | Published - Feb 2013 |
Keywords
- B-cell activating factor
- Blys
- Lymphoma
- S
- Salivary glands
ASJC Scopus subject areas
- Rheumatology
- Pharmacology (medical)